CXCR4 and neoplasm: Lexiscan was used to pharmacologically increase BBB permeability, AMD3100 was utilized to target CXCR4 overexpressed on tumor cells, and a neutrophil elastase (NE)-cleavable peptide was used for controlled drug release at the tumor.